The approval of risankizumab represents the first IL-23 approved for IBD.
With the approval of risankizumab (SKYRIZI) by the US Food and Drug Administration (FDA), the first interleukin-23 (IL-23) medication approved for patients with Crohn's disease,there may be a new wave of drug development for inflammatory bowel disease (IBD).
Many clinicians and researchers are excited about the possibility of new IL-23’s for both Crohn’s disease and ulcerative colitis.
But there are also other treatment options emerging, which is a lot of the discussion at the 2022 American College of Gastroenterology (ACG) Annual Meeting in Charlotte.
In an interview with HCPLive®, Jordan E. Axelrad, MD, MPH, NYU Langone, talked about the approval of risankizumab, the comparison between ustekinumab and anti-TNFs, and what the proper dosing for IBD treatments is.